{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:27:11Z","timestamp":1793755631369,"version":"4.6.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Catania","id":[{"id":"https:\/\/ror.org\/03a64bh57","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Assist Reprod Genet"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe a case of reversible azoospermia temporally associated with abrocitinib treatment in a man with severe atopic dermatitis (AD) and discuss its potential implications for male reproductive safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Case report.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient<\/jats:title>\n                    <jats:p>A 38-year-old normal-weight man with highly refractory AD, a history of neonatal orchidopexy, and primary infertility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Clinical, hormonal, and semen evaluation before and after discontinuation of abrocitinib therapy (200mg\/day).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Semen parameters and reproductive hormone profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two consecutive semen analyses performed during abrocitinib treatment demonstrated azoospermia. Baseline endocrine evaluation showed elevated follicle-stimulating hormone (FSH; 12.3 mIU\/mL), suggestive of seminiferous tubule dysfunction. Abrocitinib was discontinued, and reassessment after 3 months revealed complete recovery of spermatogenesis, with a sperm concentration of 50 million\/mL. Although isolated teratozoospermia persisted, FSH levels normalized (8.6 mIU\/mL) and inhibin B increased markedly (from 58 to 135 pg\/mL), consistent with improved Sertoli cell function. The temporal association between drug withdrawal and recovery supports a potential reversible effect on spermatogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is, to our knowledge, the first report describing reversible azoospermia temporally associated with abrocitinib therapy. Although causality cannot be established from a single observation, this case raises a potential safety signal regarding the effects of selective JAK1 inhibition on male reproductive function. Further preclinical studies, pharmacovigilance analyses, and prospective clinical investigations are warranted to determine whether prolonged or high-dose abrocitinib exposure may adversely affect spermatogenesis in susceptible individuals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10815-026-03993-0","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T13:46:35Z","timestamp":1785937595000},"page":"3001-3006","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reversible azoospermia associated with the selective JAK1 inhibitor abrocitinib: a case report"],"prefix":"10.1007","volume":"43","author":[{"given":"Giuseppe","family":"Seminara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Cannarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo Eugenio","family":"Calogero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Aversa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"3993_CR1","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","volume":"148","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148:927\u201340.","journal-title":"J Allergy Clin Immunol"},{"key":"3993_CR2","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/all.16009","volume":"79","author":"S M\u00fcller","year":"2024","unstructured":"M\u00fcller S, Maintz L, Bieber T. Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs. Allergy. 2024;79:1501\u201315.","journal-title":"Allergy"},{"key":"3993_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, Bieber T, Thyssen JP, Yosipovitch G, Flohr C, Magnolo N, Maari C, Feeney C, Biswas P, Tatulych S, Valdez H, Rojo R. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396:255\u201366.","journal-title":"Lancet"},{"key":"3993_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, Hong HC, Katoh N, Valenzuela F, DiBonaventura M, Bratt TA, Zhang F, Clibborn C, Rojo R, Valdez H, Kerkmann U. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400:273\u201382.","journal-title":"Lancet"},{"key":"3993_CR5","doi-asserted-by":"publisher","DOI":"10.1242\/dev.167643","volume":"146","author":"SC Herrera","year":"2019","unstructured":"Herrera SC, Bach EA. JAK\/STAT signaling in stem cells and regeneration: from Drosophila to vertebrates. Development. 2019;146: dev167643.","journal-title":"Development"},{"key":"3993_CR6","doi-asserted-by":"publisher","first-page":"R569","DOI":"10.1016\/S0960-9822(02)01057-6","volume":"12","author":"JC Hombr\u00eda","year":"2002","unstructured":"Hombr\u00eda JC, Brown S. The fertile field of Drosophila Jak\/STAT signalling. Curr Biol. 2002;12:R569\u201375.","journal-title":"Curr Biol"},{"key":"3993_CR7","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1007\/s10815-020-01912-5","volume":"37","author":"BK Binsila","year":"2020","unstructured":"Binsila BK, Selvaraju S, Ghosh SK, Ramya L, Arangasamy A, Ranjithkumaran R, Bhatta R. EGF, GDNF, and IGF-1 influence the proliferation and stemness of ovine spermatogonial stem cells in vitro. J Assist Reprod Genet. 2020;37:2615\u201330.","journal-title":"J Assist Reprod Genet"},{"key":"3993_CR8","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s12079-023-00726-1","volume":"17","author":"P Mol","year":"2023","unstructured":"Mol P, Balaya RDA, Dagamajalu S, Babu S, Chandrasekaran P, Raghavan R, Suresh S, Ravishankara N, Raju AH, Nair B, Modi PK, Mahadevan A, Prasad TSK, Raju R. A network map of GDNF\/RET signaling pathway in physiological and pathological conditions. J Cell Commun Signal. 2023;17:1089\u201395.","journal-title":"J Cell Commun Signal"},{"key":"3993_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ydbio.2005.05.042","volume":"284","author":"J Wu","year":"2005","unstructured":"Wu J, Jester WF Jr, Orth JM. Short-type PB-cadherin promotes survival of gonocytes and activates JAK-STAT signalling. Dev Biol. 2005;284:437\u201350.","journal-title":"Dev Biol"},{"key":"3993_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12860-023-00482-5","volume":"24","author":"A Zareifard","year":"2023","unstructured":"Zareifard A, Beaudry F, Ndiaye K. Janus Kinase 3 phosphorylation and the JAK\/STAT pathway are positively modulated by follicle-stimulating hormone (FSH) in bovine granulosa cells. BMC Mol Cell Biol. 2023;24:21.","journal-title":"BMC Mol Cell Biol"},{"key":"3993_CR11","unstructured":"European Medicines Agency. EMA Jyseleca Public Assessment Report. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/jyseleca-eparpublic-assessment-reporten.pdf.2020 . Accessed 8 Jun 2026."},{"key":"3993_CR12","unstructured":"World Health Organization. WHO laboratory manual for the examination and processing of human semen. 6th ed. Geneva; 2021."},{"key":"3993_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102131","volume":"22","author":"M Marino","year":"2024","unstructured":"Marino M, Cannarella R, Condorelli RA, Crafa A, La Vignera S, Calogero AE. New insights of target therapy: effects of tyrosine kinase inhibitors on male gonadal function: a systematic review. Clin Genitourin Cancer. 2024;22: 102131.","journal-title":"Clin Genitourin Cancer"},{"key":"3993_CR14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0140-6736(84)91752-5","volume":"1","author":"T Sch\u00fcrmeyer","year":"1984","unstructured":"Sch\u00fcrmeyer T, Knuth UA, Belkien L, Nieschlag E. Reversible azoospermia induced by the anabolic steroid 19-nortestosterone. Lancet. 1984;1:417\u201320.","journal-title":"Lancet"},{"key":"3993_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3109\/13625189609150672","volume":"1","author":"O Arango","year":"1996","unstructured":"Arango O, Bielsa O, Grau S, Gelabert-Mas A. Reversible azoospermia in a patient treated with triazolam. Eur J Contracept Reprod Health Care. 1996;1:293\u20134.","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"3993_CR16","volume":"13","author":"TE Abdalla","year":"2021","unstructured":"Abdalla TE, Kotsonis D, Best J, Ramasamy R, Wood E. Stimulant-induced pituitary failure and reversible azoospermia. Cureus. 2021;13: e14269.","journal-title":"Cureus"},{"key":"3993_CR17","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/ard-2023-224017","volume":"82","author":"W Reinisch","year":"2023","unstructured":"Reinisch W, Hellstrom W, Dolhain RJEM, Sikka S, Westhovens R, Mehta R, Ritter T, Seidler U, Golovchenko O, Simanenkov V, Garmish O, Jeka S, Moravcov\u00e1 R, Rajendran V, Le Brun FO, Arterburn S, Watkins TR, Besuyen R, Vanderschueren D. Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies. Ann Rheum Dis. 2023;82:1049\u201358.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3993_CR18","doi-asserted-by":"publisher","first-page":"e2345","DOI":"10.1002\/bdr2.2345","volume":"116","author":"CJ Bowman","year":"2024","unstructured":"Bowman CJ, Campion SN, Catlin NR, Nowland WS, Stethem CM, Radi ZA, Cappon GD. Reversible effects on female rat fertility with abrocitinib, a Janus kinase 1 inhibitor. Birth Defects Res. 2024;116(5):e2345. https:\/\/doi.org\/10.1002\/bdr2.2345.","journal-title":"Birth Defects Res"},{"key":"3993_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ard-2023-223850","volume":"83","author":"M Bonelli","year":"2024","unstructured":"Bonelli M, Kerschbaumer A, Kastrati K, Ghoreschi K, Gadina M, Heinz LX, Smolen JS, Aletaha D, O\u2019Shea J, Laurence A. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. Ann Rheum Dis. 2024;83:139\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3993_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-018-0368-4","volume":"16","author":"X Wang","year":"2018","unstructured":"Wang X, Zhang X, Hu L, Li H. Exogenous leptin affects sperm parameters and impairs blood testis barrier integrity in adult male mice. Reprod Biol Endocrinol. 2018;16(1): 55. https:\/\/doi.org\/10.1186\/s12958-018-0368-4.","journal-title":"Reprod Biol Endocrinol"},{"key":"3993_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00224","volume":"10","author":"SB Meroni","year":"2019","unstructured":"Meroni SB, Galardo MN, Rindone G, Gorga A, Riera MF, Cigorraga SB. Molecular mechanisms and signaling pathways involved in Sertoli cell proliferation. Front Endocrinol (Lausanne). 2019;10: 224.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Journal of Assisted Reproduction and Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-026-03993-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10815-026-03993-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-026-03993-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:04:15Z","timestamp":1793754255000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10815-026-03993-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3993"],"URL":"https:\/\/doi.org\/10.1007\/s10815-026-03993-0","relation":{},"ISSN":["1058-0468","1573-7330"],"issn-type":[{"value":"1058-0468","type":"print"},{"value":"1573-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"10 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable as this is a single patient case report with written permission from the patient.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from the individual participant included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The participant has consented to the submission of the case report to the journal.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}